MENU
Close
Disease Overview
Creative Biolabs explores main signaling pathways in various diseases including cancers, immune diseases, neurodegenerative diseases, and infectious diseases. Targeted therapies and diagnostic methods related to these diseases are also summarized
-
Support
- FAQs
- Resource
- Engineered Antibody Overview
- Therapeutic Antibody Overview
- Why Recombinant Monoclonal Antibodies?
- Biosimilars of Monoclonal Antibodies
- Vβ 8 & M2 BsAb Overview
- Abciximab Overview
- Rovelizumab Overview
- Vatelizumab Overview
- Edobacomab Overview
- Efungumab Overview
- Nebacumab Overview
- Parsatuzumab Overview
- Ascrinvacumab Overview
- Priliximab Overview
- Arcitumomab Overview
- Altumomab Overview
- Sulesomab Overview
- Besilesomab Overview
- Sevirumab Overview
- Lacnotuzumab Overview
- Urtoxazumab Overview
- Briakinumab Overview
- Certolizumab Pegol Overview
- Efalizumab Overview
- Obiltoxaximab Overview
- Odulimomab Overview
- Ralpancizumab Overview
- Sofituzumab Vedotin Overview
- Tezepelumab Overview
- Refanezumab Overview
- Bapineuzumab Overview
- Capromab Pendetide Overview
- Dinutuximab Overview
- Duligotuzumab Overview
- Elgemtumab Overview
- Ifabotuzumab Overview
- Polatuzumab Vedotin Overview
- Ponezumab Overview
- Vorsetuzumab Mafodotin Overview
- Vorsetuzumab Overview
- Olendalizumab Overview
- Afelimomab Overview
- Anatumomab Mafenatox Overview
- Blosozumab Overview
- Brentuximab Vedotin Overview
- Carotuximab Overview
- Denosumab Overview
- Enavatuzumab Overview
- Golimumab Overview
- Icrucumab Overview
- Indatuximab Ravtansine Overview
- Infliximab Overview
- Iratumumab Overview
- Lerdelimumab Overview
- Roledumab Overview
- Satumomab Overview
- Satumomab Pendetide Overview
- Siplizumab Overview
- Lifastuzumab Vedotin Overview
- Minretumomab Overview
- Motavizumab Overview
- Naptumomab Estafenatox Overview
- Ozanezumab Overview
- Palivizumab Overview
- Tefibazumab Overview
- Tenatumomab Overview
- Afasevikumab Overview
- Andecaliximab Overview
- Anrukinzumab Overview
- Apolizumab Overview
- Bertilimumab Overview
- Cantuzumab Mertansine Overview
- Clenoliximab Overview
- Codrituzumab Overview
- Dezamizumab Overview
- Diridavumab Overview
- Ecromeximab Overview
- Eldelumab Overview
- Enoblituzumab Overview
- Enokizumab Overview
- Ensituximab Overview
- Fezakinumab Overview
- Inolimomab Overview
- Keliximab Overview
- Lorvotuzumab Mertansine Overview
- Ontuxizumab Overview
- Otlertuzumab Overview
- Panobacumab Overview
- Pascolizumab Overview
- Pemtumomab Overview
- Plozalizumab Overview
- Prezalumab Overview
- Ramucirumab Overview
- Samalizumab Overview
- Yttrium (90 Y) Clivatuzumab Tetraxetan Overview
- Disease Overview
- Protocol & Troubleshooting
- Immunoassay - Protocol & Troubleshooting
- Live Cell Imaging - Protocol & Troubleshooting
- Multiplex Bead-Based Assay - Protocol & Troubleshooting
- Neutralization - Protocol & Troubleshooting
- Protein Purification - Protocol & Troubleshooting
- Tissue Culture - Protocol & Troubleshooting
- Turbidimetry - Protocol & Troubleshooting
- Immunoblotting - Protocol & Troubleshooting
- Immunocytochemistry - Protocol & Troubleshooting
- Immunodiffusion - Protocol & Troubleshooting
- Immunofluorescence - Protocol & Troubleshooting
- Immunohistochemistry - Protocol & Troubleshooting
- Immunohistochemistry-Frozen - Protocol & Troubleshooting
- Immunohistochemistry-Paraffin - Protocol & Troubleshooting
Disease Overview
Cancers Immune Diseases Drug Resistance: Antineoplastic Substance Dependence Endocrine and Metabolic Diseases Neurodegenerative Diseases
Thyroid Cancer
Colorectal Cancer
Pancreatic Cancer
Gastric Cancer
Prostate Cancer
Bladder Cancer
Non-small Cell Lung Cancer
Hepatocellular Carcinoma
Breast Cancer
Endometrial Cancer
Asthma
Rheumatoid Arthritis
Inflammatory Bowel Disease (IBD)
Systemic Lupus Erythematosus
Primary Immunodeficiency
Autoimmune Thyroid Disease
Allograft Rejection
Graft-versus-host Disease 
EGFR Tyrosine Kinase Inhibitor Resistance
Endocrine Resistance
Morphine Addiction
Cocaine Addiction
Amphetamine Addiction
Alcoholism
Insulin Resistance
AGE-RAGE Signaling Pathway in Diabetic Complications
Type I Diabetes Mellitus
Maturity Onset Diabetes of the Young
Cushing Syndrome
Amyotrophic Lateral Sclerosis (ALS)For research use only. Not intended for any clinical use.